Who
Lawrence M. Alleva
Director
Company insider
Files Form 4 as: Director, Galera Therapeutics; Director, Bright Horizons Family Solutions; Director, Mersana Therapeutics; Director, Adaptimmune Therapeutics; Director, Tesaro; Director, Synlogic.
In numbers
- Trades disclosed
- 170
- Buys
- 16
- Sells
- 3
- Bought
- $621K
- Sold
- $1.2M
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 3 Jul 2012
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | Galera TherapeuticsBiotechnology | SEC FORM 4 Code D | —11 | filing |
| 3 Aug 2026filed 5 Aug 2026 | Galera TherapeuticsBiotechnology | SEC FORM 4 Code D | —40 | filing |
| 3 Aug 2026filed 5 Aug 2026 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —240 | filing |
| 3 Aug 2026filed 5 Aug 2026 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —240 | filing |
| 3 Aug 2026filed 5 Aug 2026 | Galera TherapeuticsBiotechnology | SEC FORM 4 Code D | —11 | filing |
| 3 Aug 2026filed 5 Aug 2026 | Galera TherapeuticsBiotechnology | SEC FORM 4 Code D | —40 | filing |
| 3 Jun 2026filed 5 Jun 2026 | BFAM Bright Horizons Family SolutionsConsumer Services | SEC FORM 4 Code A | —2,096 | filing |
| 3 Jun 2026filed 5 Jun 2026 | BFAM Bright Horizons Family SolutionsConsumer Services | SEC FORM 4 Code A | —2,096 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana TherapeuticsBiotechnology | SEC FORM 4 Code U | —578 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —368 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —133 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,002 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —546 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,800 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —181 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —734 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —215 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —561 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —310 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana TherapeuticsBiotechnology | SEC FORM 4 Code U | —84 | filing |
News
No headline names them, or the companies they trade most, lately.